AUS
NZ
UK
CA
USA
IND
Highlights
- Microba Life Sciences has partnered with Midnight Health to offer Vidality, a truly personalised solution powered by its technology.
- nib Holdings-backed digital healthcare firm Midnight Health will be responsible for promoting, marketing, and selling Vidality.
Microba Life Sciences Limited (ASX:MAP) is all set to roll out a world-first subscription-based personalised consumer health service called Vidality.
In a significant development, the company joined hands with Midnight Health, a digital healthcare firm backed by nib Holdings Limited (ASX:NHF), concerning Vidality.
Microba is a precision microbiome company focused on the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services on a global basis. The company is committed to enhancing human health with world-leading technology for measuring the human gut microbiome.
Midnight Health has a patient-led digital platform through which the firm delivers innovative online healthcare solutions.
Do read: Two ASX healthcare stocks AHX & RHC expand business with new acquisitions
Vidality: Bringing science and personalisation to healthcare industry
The agreement has been signed after a successful pilot focused on testing the service model and product offering. The pilot further exhibited Microba’s scalable technology and potential to deliver evidence-based gut health solutions.
The partnership will aid in providing a tailored health service to the Australian consumer market.
The agreement, which is for an initial period of three years, underlies the following:
Data source: company update
The model will be delivered through trained and registered pharmacists. It will be a personalised, pharmacy-integrated service model, bringing a level of science and personalisation to an industry which generally provides one-size-fits-all solutions to its customers.
CEO of Midnight Health, Nic Blair, highlighted the strong demand for innovative online and personalised healthcare solutions. The firm already caters to over 13,000 subscribers across its existing brands with strong month-on-month growth. Many of its customers are looking for gut health solutions, Blair added.
Commenting on the partnership, Microba CEO, Dr Luke Reid, said:
“Consumers are seeking personalised, evidence-based solutions to support their gut health. Together with Midnight Health, we are excited to bring the Vidality product to consumers, a truly personalised solution powered by our technology”.
Also read: WFL, OSL, AVE: Three ASX healthcare stocks with over 20% QTD returns
